BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 70,000 shares of the stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $82.52, for a total value of $5,776,400.00. Following the completion of the transaction, the chief executive officer now owns 393,368 shares of the company’s stock, valued at $32,460,727.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Tuesday, November 8th, Jean Jacques Bienaime sold 140,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $82.67, for a total value of $11,573,800.00.
  • On Friday, October 28th, Jean Jacques Bienaime sold 120,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $81.30, for a total value of $9,756,000.00.
  • On Monday, October 17th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.39, for a total value of $3,516,193.74.
  • On Friday, October 14th, Jean Jacques Bienaime sold 64,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $86.96, for a total value of $5,576,310.00.
  • On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $93.65, for a total value of $4,975,156.25.
  • On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $95.34, for a total value of $13,096,665.12.
  • On Tuesday, August 16th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $91.49, for a total value of $3,812,022.34.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 91.83 on Thursday. The company’s market capitalization is $15.79 billion. BioMarin Pharmaceutical Inc. has a 1-year low of $62.12 and a 1-year high of $111.84. The company’s 50 day moving average price is $88.21 and its 200-day moving average price is $89.15.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 27th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.13. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. The business had revenue of $279.90 million for the quarter, compared to the consensus estimate of $289.70 million. During the same period last year, the business posted ($0.60) EPS. The company’s revenue was up 34.0% compared to the same quarter last year. On average, equities analysts forecast that BioMarin Pharmaceutical Inc. will post ($3.73) earnings per share for the current year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of BioMarin Pharmaceutical by 3.1% in the second quarter. Vanguard Group Inc. now owns 11,448,690 shares of the company’s stock valued at $890,708,000 after buying an additional 346,369 shares in the last quarter. Jennison Associates LLC increased its stake in shares of BioMarin Pharmaceutical by 7.2% in the third quarter. Jennison Associates LLC now owns 9,702,200 shares of the company’s stock valued at $897,648,000 after buying an additional 650,956 shares in the last quarter. State Street Corp increased its stake in shares of BioMarin Pharmaceutical by 1.9% in the second quarter. State Street Corp now owns 3,349,037 shares of the company’s stock valued at $260,556,000 after buying an additional 62,294 shares in the last quarter. Palo Alto Investors LLC increased its stake in shares of BioMarin Pharmaceutical by 29.6% in the second quarter. Palo Alto Investors LLC now owns 1,737,399 shares of the company’s stock valued at $135,170,000 after buying an additional 397,052 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of BioMarin Pharmaceutical by 6.9% in the third quarter. Northern Trust Corp now owns 1,294,318 shares of the company’s stock valued at $119,750,000 after buying an additional 83,584 shares in the last quarter. Institutional investors and hedge funds own 93.18% of the company’s stock.

A number of brokerages have recently issued reports on BMRN. Vetr downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $103.86 price objective for the company. in a research report on Monday, August 1st. Barclays PLC raised their price objective on BioMarin Pharmaceutical from $105.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Stifel Nicolaus raised their price objective on BioMarin Pharmaceutical from $107.00 to $113.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Piper Jaffray Cos. raised their price objective on BioMarin Pharmaceutical from $107.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Finally, Jefferies Group raised their price objective on BioMarin Pharmaceutical from $116.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $115.16.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.